Compare Inovio Pharmaceuticals Inc (INO) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Transocean Ltd — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Transocean Ltd trades at $5.11 (market cap $5.56B). The key difference: Transocean Ltd is far larger — about 62.3× Inovio Pharmaceuticals Inc's market cap, and Transocean Ltd is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | RIG | |
|---|---|---|
Market Cap | $89.27M | $5.56B |
Sector | Health | Technology |
52-Week High | $2.87 | $7.58 |
52-Week Low | $1.05 | $2.64 |
Enterprise Value | $60.28M | $10.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Transocean Ltd. (RIG) trades at $5.02, down 2.33% on the day, reflecting a bearish technical trend. The company reported a net loss of $2.92 billion in 2025 despite $3.97 billion in revenue, with a negative net income margin of -66.79%. Recent news highlights a significant $1 billion contract with Equinor and a pending merger with Valaris, aimed at reducing leverage and generating synergies. Analyst consensus is mixed, with a $7.00 price target suggesting potential upside from current levels.
The outlook for RIG hinges on successful execution of its merger and contract backlog conversion to profitability. Opportunities include a strong $7 billion backlog and operational momentum, but risks persist from sustained net losses, high debt, and oil price volatility. Investors should weigh the potential for deleveraging and synergy benefits against ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
